May 8, 2019 • 4:10pm EDT

Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results

-- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 -- -- Conference Call Today, May 8, 2019, at 4:30 p.m. (ET) -- ROCKVILLE, Md., May 8, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial results for the three months ended March 31, 2019. ...